Developing Innovative Cancer Immunotherapies

Learn about our pipeline

Clinical Trials
Recruiting

Developing innovative internally discovered small molecule drug candidates as well as antibody candidates that target immuno-oncology pathways

learn more

We’re Hiring!
Growth

Arcus Biosciences is an exciting young company founded on the vision of creating new cancer therapeutics through the translation of unexploited insights in immunology.

learn more

MEDIA

Adenosine dreams fueling new approaches in cancer; Arcus embarks on phase I

By Randy Osborne, Staff Writer

Although Merck & Co. Inc. continues to chalk up investor-pleasing sales with Keytruda (pembrolizumab) and Bristol-Myers Squibb Co. (BMS) keeps doing well with Opdivo (nivolumab), researchers have yet to strike upon the best combinations with other agents.

Keep Reading

PIPELINE

Program

Indication

Discovery

Preclinical

Phase 1 Safety
Dose-Escalation

Phase 1b
Dose-Expansion/
Efficacy Signal

AB928 (Dual Adenosine Receptor Antagonist) LEARN MORE

AB928+AB122

CRPC, RCC

Title

75%

AB928+AB122+Carbo/Pem

NSCLC

Title

65%

AB928+mFOLFOX

CRC, GEC1

Title

75%

AB928+PLD2

TNBC, Ovarian1

Title

75%

AB928+PLD2+IPI-549

TNBC

Title

52%

AB680 (Small Molecule CD73 Inhibitor) LEARN MORE

AB680+AB122+Gem/nab-paclitaxel

Pancreatic

2H19: Initiate Ph1 Safety Dose-Escalation

52%

AB122 (Anti-PD-1 Antibody) LEARN MORE

AB122

Biomarker-selected
(tumor-type agnostic)

2H19: Initiate Safety & Efficacy Evaluations

75%

AB154 (Anti-TIGIT Antibody) LEARN MORE

AB154+AB122

NSCLC

Title

65%

Discovery and Preclinical Small Molecules

AB610 (PI3Kγ Inhibitor)

Oncology Indications

Title

20%

HIF-2α Antagonist

Oncology Indications

Title

15%

Axl Inhibitor

Oncology Indications

Title

10%

PAK4 Inhibitor

Oncology Indications

Title

5%
  1. Potential Investigator-Sponsored Trial(s) (IST).
  2. Pegylated liposomal doxorubicin.

Arcus has significant expertise in immunology, medicinal chemistry, biochemistry, enzymology, pharmacology, and structural biology.

Meet Our Leadership